Tilray Brands (TLRY) Capital Expenditures Growth (1y) (2018 - 2025)
Tilray Brands (TLRY) Capital Expenditures Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Tilray Brands | 523.93 Mn | 289.30 Mn | 90.52 Mn | 60.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2025 | -34.80% |
| Feb 28, 2025 | 51.28% |
| Nov 30, 2024 | -7.22% |
| Aug 31, 2024 | 62.24% |
| May 31, 2024 | -21.73% |
| Feb 29, 2024 | 1,011.79% |
| Nov 30, 2023 | 29.14% |
| Aug 31, 2023 | 38.40% |
| May 31, 2023 | 121.77% |
| Feb 28, 2023 | -81.43% |
| Nov 30, 2022 | -39.83% |
| Aug 31, 2022 | -81.61% |
| May 31, 2022 | 13.17% |
| Nov 30, 2021 | -52.60% |
| Aug 31, 2021 | 16.92% |
| May 31, 2021 | -89.78% |
| May 31, 2020 | -58.90% |
| Mar 31, 2020 | 102.84% |
| Sep 30, 2019 | 145.53% |
| Mar 31, 2019 | -29.86% |